Wanbury Limited is India’s fastest growing pharmaceutical company amongst the ‘Top 50 Companies’ as per ORG-IMS, with presence in global Active Pharmaceutical Ingredients (API) market and domestic branded formulations. Its key brands, each falling in the sales range of Rs. 12-28 crore, include iron supplement CPink, osteoporosis drug Adtrol Plus, Rabiplus, and folic acid Folinine.

The company posted a turnaround for Q2FY17 with a net profit of Rs.7 crore v/s loss of Rs.2.4 crore in previous Q2. This was ona  14% rise in total income at Rs.122 crore with EBITDA margin showing a good 120 bps jump up at 9.9%.

The market is enthused with the performance, which explains why the stock was locked on the 5% upper circuit at Rs.41.55 the moment it opened for trading today morning.